Clinical trials: Untreated
Leukemia, Myelodysplastic Syndromes
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00077116
- Testing
- busulfan, cyclophosphamide, cytarabine
- Where
- 9 sites in Belgium, Germany and 2 more
- Volunteers
- 31 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Renal Cell Carcinoma, RCC
A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma
Study the efficacy and toxicity of SABR treatment for oligometastatic/oligoprogressive renal cell carcinoma; investigate the effectiveness and safety of SABR combined with targeted immunotherapy; conduct stratified analysis to…
- Conditions
- Renal Cell Carcinoma, RCC, Kidney Cancer
- Trial name
- NCT06585878
- Testing
- Stereotactic Ablative Radiotherapy (SABR)
- Volunteers
- 60 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
This phase I/II trial is studying the side effects and best way to give nilotinib when given alone or sequentially after imatinib mesylate after donor stem cell transplant in treating patients with acute lymphoblastic leukemia or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT00702403
- Testing
- nilotinib, imatinib mesylate, pharmacological study
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can find cancer cells and carry cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00770224
- Testing
- rituximab, tositumomab, cyclophosphamide
- Where
- 114 sites in United States
- Volunteers
- 87 people
- Sponsor
- SWOG Cancer Research Network
Squamous Non-Small Cell Lung Cancer
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in adults with advanced or metastatic…
- Trial name
- NCT02106546
- Testing
- Carboplatin, Veliparib, Paclitaxel
- Where
- 225 sites in United States, Australia and 36 more
- Volunteers
- 970 people
- Sponsor
- AbbVie
Lymphoma, Neuroblastoma
Whole-Body MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or Lymphoma
RATIONALE: New imaging procedures, such as whole-body MRI, may improve the ability to detect metastatic cancer and determine the extent of disease.
- Conditions
- Lymphoma, Neuroblastoma, Sarcoma
- Trial name
- NCT00072488
- Testing
- computed tomography, magnetic resonance imaging, positron emission tomography
- Where
- 21 sites in United States, Canada
- Volunteers
- 226 people
- Sponsor
- American College of Radiology Imaging Network
Hemophilia A
Hemophilia Inhibitor Previously Untreated Patient Study
Hemophilia A is a congenital bleeding disorder caused by deficiency of factor VIII (FVIII) and is treated by replacement therapy with FVIII concentrate.
- Trial name
- HIPS (NCT01652027)
- Testing
- FVIII concentrate
- Where
- 17 sites in United States, Austria and 3 more
- Volunteers
- 25 people
- Sponsor
- The University of Texas Health Science Center, Houston
Metastatic Colorectal Cancer
Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer
The purpose of this study is to determine the efficacy and safety of bevacizumab/capecitabine/oxaliplatin combination in metastatic or recurrent Korean colorectal cancer.
- Trial name
- NCT00378066
- Testing
- Bevacizumab
- Where
- 6 sites in South Korea
- Volunteers
- 49 people
- Sponsor
- Asan Medical Center
Brain and Central Nervous System Tumors
Surgery Plus Radiation Therapy With or Without Chemotherapy in Treating Children With Primitive Neuroectodermal Tumors of the CNS
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003859
- Testing
- carboplatin, cyclophosphamide, etoposide
- Where
- United Kingdom
- Volunteers
- 230 people
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
Visible Light Exposure on Healthy Back Skin
Determine the Photoprotection Efficacy of Seven Sunscreen Products Under Visible Light Exposure.
To evaluate the protective effect of seven sunscreens on the pigmentation caused by visible light in comparison to an untreated control zone in healthy volunteers.
- Trial name
- NCT06796179
- Testing
- Visible Light Exposure - Treated zones with sunscreen products, Visible Light Exposure - Untreated zone
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with previously untreated metastatic pancreatic cancer.
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreas Metastases
- Trial name
- NABPLAGEMD (NCT03415854)
- Testing
- Paricalcitol (Zemplar)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- HonorHealth Research Institute
Unresectable or Metastatic Melanoma
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to Ipilimumab alone.
- Trial name
- NCT01844505
- Testing
- Nivolumab, Ipilimumab
- Where
- 150 sites in United States, Australia and 20 more
- Volunteers
- 945 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myeloproliferative Disorders, Leukemia
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT01137643
- Testing
- biologic sample preservation procedure, cytology specimen collection procedure
- Where
- United States
- Volunteers
- 15,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lymphoma
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00896519
- Testing
- rituximab, sargramostim, cyclophosphamide
- Volunteers
- 30 people
- Sponsor
- French Innovative Leukemia Organisation
Leukemia, Myeloid, Acute
Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia
This is an open label study to assess the suitability of CPX-351 as first intensive therapy in elderly (age ≥60 years) patients with AML. Patients may have received prior AML treatment with non-intensive regimens, e.g.
- Trial name
- NCT03335267
- Testing
- CPX-351
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Weill Medical College of Cornell University
Lymphoma, Non-Hodgkin
Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab
This is a single-arm, single institution, phase II study of fludarabine monophosphate followed by Iodine I 131 Tositumomab for patients with previously untreated, advanced-stage (stage III or IV) low-grade, transformed low-grade…
- Trial name
- NCT00933335
- Testing
- Tositumomab and Iodine I 131 Tositumomab
- Volunteers
- 38 people
- Sponsor
- GlaxoSmithKline
Leukemia, Myelodysplastic Syndromes
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002517
- Testing
- cytarabine, daunorubicin hydrochloride, dexamethasone
- Where
- 23 sites in Belgium, France and 1 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma, Large B-Cell, Diffuse
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
To evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and…
- Trial name
- ROBUST (NCT02285062)
- Testing
- lenalidomide, Rituximab, Cyclophosphamide
- Where
- 158 sites in United States, Australia and 19 more
- Volunteers
- 570 people
- Sponsor
- Celgene
Vulvovaginal Candidiasis (VVC)
An Investigation to Evaluate the Clinical Performance and Safety of pHyph in Adult Women With Vulvovaginal Candidiasis Compared With an Untreated Control Group
The goal of this clinical trial is to learn if pHyph works to reduce signs and symptoms of vulvovaginal candidiasis (thrush). It will also learn about the safety of pHyph.
- Trial name
- NCT07405853
- Testing
- pHyph
- Where
- 3 sites in Sweden
- Volunteers
- 48 people
- Sponsor
- Gedea Biotech AB
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
This is a combination study to evaluate sapacitabine administered in alternating cycles with decitabine in previously untreated Acute Myeloid Leukemia (AML) or concomitantly with venetoclax in previously treated AML or MDS
- Trial name
- NCT01211457
- Testing
- sapacitabine and decitabine (Part 1 - completed), sapacitabine and venetoclax (Part 2 - recruiting)
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.